(Q36720873)

15 August 2017

1 reference

title

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress (English)

1 reference

15 August 2017

1 reference

2

Evanthia Galanis

1 reference

15 August 2017

Ta-Chiang Liu

1

1 reference

PubMed ID

17259931

15 August 2017

David Kirn

series ordinal

3

1 reference

15 August 2017

1 February 2007

1 reference

Nature Clinical Practice Oncology

15 August 2017

1 reference

15 August 2017

4

1 reference

15 August 2017

101-117

1 reference

15 August 2017

2

1 reference

Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Possible effect of measles on leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Regression of Burkitt's lymphoma in association with measles infection.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Regression of Hodgkin's disease after measles

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Viruses in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Remission of chronic lymphocytic leukemia after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Hodgkin's disease: therapeutic role of measles vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Therapeutic role of measles vaccine in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

West Nile, Ilheus, and Bunyamwera virus infections in man.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Treatment of human cancer with mumps virus

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

The limited role of attenuated smallpox virus in the management of advanced malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Use of Vaccinia Virus in the Treatment of Metastatic Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Treatment of primary melanoma by intralesional vaccinia before excision

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

H-1 VIRUS VIREMIA IN THE HUMAN.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Measles and leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0736

7 January 2021

Identifiers

DOI

10.1038/NCPONC0736

1 reference

15 August 2017

1 reference

PubMed ID

17259931